169 related articles for article (PubMed ID: 29260625)
1. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab.
Jotatsu T; Oda K; Yamaguchi Y; Noguchi S; Kawanami T; Kido T; Satoh M; Yatera K
Immunotherapy; 2018 Feb; 10(2):85-91. PubMed ID: 29260625
[TBL] [Abstract][Full Text] [Related]
2. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.
Kashima J; Okuma Y; Shimizuguchi R; Chiba K
Cancer Immunol Immunother; 2018 Jan; 67(1):61-65. PubMed ID: 28913619
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report.
Khatri S; Alom M; Kashfi S; Atallah J; Goswami G
J Investig Med High Impact Case Rep; 2023; 11():23247096231194401. PubMed ID: 37642143
[TBL] [Abstract][Full Text] [Related]
4. [Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer:
A Case Report and Literature Review].
Cai J; Yang G; Zhang X; Liu L; Yan M
Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):717-720. PubMed ID: 37985158
[TBL] [Abstract][Full Text] [Related]
5. No need to hesitate: immune-related neutropenia and thrombocytopenia that improved by corticosteroids.
Kanai O; Nakatani K; Fujita K; Okamura M; Mio T
Respirol Case Rep; 2021 Jul; 9(7):e00799. PubMed ID: 34123387
[TBL] [Abstract][Full Text] [Related]
6. [Unexplained reduction in the general condition of a female lung cancer patient].
Brägelmann J; Becker S; Stenzel D; Budahn A
Inn Med (Heidelb); 2024 Jun; 65(6):612-616. PubMed ID: 38240815
[TBL] [Abstract][Full Text] [Related]
7. [Alterations of thyroid function in cancer patients: a case of hypothyroidism during immunotherapy.].
Rossini G; Zuppi P; Ramponi S; Garufi C; Grillo LR; Baldelli R
Recenti Prog Med; 2023 Dec; 114(12):14e-17e. PubMed ID: 38031867
[TBL] [Abstract][Full Text] [Related]
8. Aspirin "Allergy"-Induced Thrombocytopenia: A Case Report.
Fu W; Xu S; Dong X; Xie Q; Gao Y
J Asthma Allergy; 2021; 14():201-205. PubMed ID: 33727833
[TBL] [Abstract][Full Text] [Related]
9. Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer.
Kataoka Y; Hirano K; Narabayashi T; Hara S; Fujimoto D; Tanaka T; Ebi N; Tomii K; Yoshioka H
Anticancer Res; 2018 Jan; 38(1):559-563. PubMed ID: 29277824
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Lee CK; Man J; Lord S; Cooper W; Links M; Gebski V; Herbst RS; Gralla RJ; Mok T; Yang JC
JAMA Oncol; 2018 Feb; 4(2):210-216. PubMed ID: 29270615
[TBL] [Abstract][Full Text] [Related]
11. A Case of Immune Thrombocytopenia as a Rare Side Effect of an Immunotherapy with PD1-Blocking Agents for Metastatic Melanoma.
Pföhler C; Eichler H; Burgard B; Krecké N; Müller CSL; Vogt T
Transfus Med Hemother; 2017 Nov; 44(6):426-428. PubMed ID: 29344020
[TBL] [Abstract][Full Text] [Related]
12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab and Ipilimumab in Advanced Melanoma.
Wolchok JD; Rollin L; Larkin J
N Engl J Med; 2017 Dec; 377(25):2503-2504. PubMed ID: 29262279
[No Abstract] [Full Text] [Related]
14. Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists.
Frigeri M; Meyer P; Banfi C; Giraud R; Hachulla AL; Spoerl D; Friedlaender A; Pugliesi-Rinaldi A; Dietrich PY
Can J Cardiol; 2018 Jan; 34(1):92.e1-92.e3. PubMed ID: 29275889
[TBL] [Abstract][Full Text] [Related]
15. Readministration of Nivolumab after Persistent Immune-related Colitis in a Patient with Recurrent Melanoma.
Fujii Y; Nishikawa Y; Nomura M; Miyamoto S; Uneno Y; Horimatsu T; Muto M
Intern Med; 2018 Apr; 57(8):1173-1176. PubMed ID: 29269640
[TBL] [Abstract][Full Text] [Related]
16. Dynamic Adaptation of Tumor Immune Response With Nivolumab Demonstrated by 18F-FDG PET/CT.
Eshghi N; Lundeen TF; Kuo PH
Clin Nucl Med; 2018 Feb; 43(2):114-116. PubMed ID: 29261621
[TBL] [Abstract][Full Text] [Related]
17. EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
Oshima Y; Tanimoto T; Yuji K; Tojo A
JAMA Oncol; 2018 Aug; 4(8):1112-1115. PubMed ID: 29327061
[TBL] [Abstract][Full Text] [Related]
18. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
19. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer.
Oya Y; Yoshida T; Kuroda H; Mikubo M; Kondo C; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Oncotarget; 2017 Nov; 8(61):103117-103128. PubMed ID: 29262550
[TBL] [Abstract][Full Text] [Related]
20. Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.
Yasuda Y; Urata Y; Tohnai R; Ito S; Kawa Y; Kono Y; Hattori Y; Tsuda M; Sakuma T; Negoro S; Satouchi M
Intern Med; 2018 May; 57(9):1269-1272. PubMed ID: 29279482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
